
Conference Coverage
about 4 hours ago
2026 Elevate Derm Summer Full Conference Recapabout 20 hours ago
2026 Elevate Derm Summer Conference Day 5 RecapLatest News
Videos

Shorts










Podcasts
Dermatology Times Digital Edition







Continuing Medical Education
All News

As we wrap up UV Safety Awareness Month, Kathleen Suozzi, MD, explains warning signs of sun damage, sunscreen myths, and new year-round protection tools—plus the newly FDA-approved bemotrizinol.

Catch Up on Coverage From Day 4 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 3 of the 3rd Annual Elevate-Derm Summer Conference

Faculty at Elevate-Derm Summer 2026 discussed the expanding role of oral JAK inhibitors in pediatric dermatology, emphasizing earlier intervention, individualized patient selection, safety monitoring, and family-centered counseling.

Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.

In July's letter from the editor in chief, Christopher Bunick, MD, PhD, breaks down why dermatology clinicians should be skilled in wound care.

Catch Up on Coverage From Day 2 of the 3rd Annual Elevate-Derm Summer Conference

Two phase 3 trials of Pfizer's ritlecitinib met co-primary end points for facial and total repigmentation in nonsegmental vitiligo at week 52, prompting plans for global regulatory filings.

In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.

RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.

Jane Yoo, MD, MPP, FAAD, shares expert tips to treat melasma in skin of color regarding sunscreen shades, hydroquinone breaks, TXA choices, and safer laser/peel decisions.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

San Diego meeting highlights inflammatory dermatoses, skin cancer, alopecia, and emerging therapeutic advances

July's FDA news was quiet, but an infant AD filing, JAK-refractory alopecia data, and a new device clearance hint at what's next.

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference





























